MF is a BCR-ABL1–negative chronic myeloproliferative neoplasm (MPN), a collection of heterogeneous cancers that includes primary MF (PMF) and secondary MF that sometimes forms in patients first diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET). The role of the JAK pathway and its aberrant activation in MF has long been appreciated. Importantly, the treatment armamentarium for MF is expanding with the emergence of new agents targeting the JAK pathway alongside other key regulators of immunity and inflammation. As such, treatment selection for MF is increasingly based on patient preference, with consideration given to treatment-related side effects, symptom burden, and transfusion dependency.
This educational initiative will update the interprofessional care team on current and emerging therapies for the treatment and management of MF, including treatment risks and benefits, barriers to adherence, and side effect monitoring and management. These concepts are coupled with education about shared decision-making strategies and other related approaches to achieve increased patient satisfaction, better adherence to treatment plans, and greater treatment engagement, as well as to enhance quality decision-making.
FDA Approval September 2023: Momelotinib as First- and Second-line Treatment
For the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia), in adults with anemia.